Description:
MMPs each have different substrate specificities within the ECM and are important in its degradation. MMP-2 mainly degrades type IV collagen and denatured collagens. MMP activity is modulated by tissue inhibitors of metalloproteinases (TIMP). Imbalanced secretion of certain MMP or disturbances in the differential control of MMP by TIMP have been implicated in the invasive potential of malignant tumors.
Applications:
Suitable for use in Western Blot, ELISA and Immunohistochemistry. Other applications not tested.
Recommended Dilutions:
Western Blot: 1-5ug/ml
Immunohistochemistry (Paraffin using PLP fixation): 1-5ug/ml Not tested in traditional formalin fixed tissues.
Immunohistochemistry (Frozen): 0.9ug/ml
Optimal dilution determined by the researcher.
Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
|
| Type | Isotype | Clone | Grade |
|---|
| Mab | IgG1,k | 2Q520 | Purified |
|
| Size | | Storage | Shipping | Source | Host |
|---|
| 100ug | | -20°C | Blue Ice | Human | Mouse |
|
| Concentration: |
| ~1mg/ml |
| Immunogen: |
| Synthetic oligopeptide corresponding to aa468-483, VTPRDKPMGPLLVATF of human MMP-2. |
| Purity: |
| Purified |
| Form |
| Supplied as a liquid in 0.1M PBS, pH 7.0, 2% BSA (protease free). |
| Specificity: |
| Recognizes the precursor and active forms of human MMP-2. Species Crossreactivity: mouse, rat, rabbit, porcine, bovine and equine MMP-2. Does not crossreact with human MMP-1, 3, 9 or 13. |
|
| Intended for research use only. Not for use in human, therapeutic, or diagnostic applications. |
1. Lalu, MM et al., (2005). Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart . European Heart Jour 26(1): 27-35. 2. Annabi, B et al, (2003). Hypoxia Promotes Murine Bone-Marrow-Derived Stromal Cell Migration and Tube Formation. Stem Cells 21: 337-347. 3. Attiga, FA., et al., (2000). Cancer Research 60: 4629-4637. 4. Iizasa, T. et al., (1999). Elevated Levels of Circulating Plasma Matrix Metalloproteinase 9 in Non-Small Cell Lung Cancer Patients. Clinical Can Res 5: 149-153. 5. Romanic, A.M. et al., (1998). Matrix Metallo proteinase Expression increases after cerebral focal ischemia in rats. Stoke 29: 1020-1030. 6. Nomura, H., et al., (1996). Int. J. Cancer 69: 9-16. 7. Nakagawa, T. et al., (1994). J. Neurosurg. 81: 69-77. 8. Fujimoto, N. et al., (1993). Clin. Chim. Acta. 221: 91-103. 9. Kawahara, E et al., (1993). Jpn. J. Cancer Res. 84: 409-418.
|
|
